What's in Ono Pharmaceutical Co. Ltd's pipeline?

Ono Pharmaceutical Co. Ltd has 36 drugs in our index: 2 marketed, 0 filed, 11 in Phase 3, 8 in Phase 2, 15 in Phase 1.

Which companies overlap with Ono Pharmaceutical Co. Ltd's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Sanofi, Canadian Cancer Trials Group, Amgen, Bayer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ono-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Ono Pharmaceutical Co. Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ono Pharmaceutical Co. Ltd pipeline: 2 marketed, 0 filed, 11 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 11 Phase 3 8 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Sivelestat sodium hydrate	Sivelestat sodium hydrate	marketed
Adlumiz	ANAMORELIN	marketed		Growth hormone secretagogue receptor type 1	Oncology
ONO-8025 (KRP-197)	ONO-8025 (KRP-197)	phase 3	Prostacyclin analog / IP receptor agonist	Prostanoid IP receptor	Cardiovascular
FOY-305	FOY-305	phase 3	Direct thrombin inhibitor	Factor IIa (Thrombin)	Cardiovascular
imidafenacin, KRP-197/ONO-8025	imidafenacin, KRP-197/ONO-8025	phase 3	Antimuscarinic	M3 receptor	Urology
Minodronic acid hydrate	Minodronic acid hydrate	phase 3	Bisphosphonate	Farnesyl pyrophosphate synthase	Bone metabolism / Osteoporosis
ONO-1101	ONO-1101	phase 3	PD-1 inhibitor	PD-1	Oncology
ONO-4059	ONO-4059	phase 3	PI3K inhibitor	PI3K (phosphoinositide 3-kinase)	Oncology
Docetaxel/Paclitaxel	Docetaxel/Paclitaxel	phase 3	Taxane (microtubule-stabilizing chemotherapy)	β-tubulin / microtubules	Oncology
ONO-5920	ONO-5920	phase 3	Prostanoid IP receptor agonist	Prostanoid IP receptor	Cardiovascular
ONO-4538	ONO-4538	phase 3	PD-1 inhibitor	PD-1	Oncology
MK-0431/ONO-5435	MK-0431/ONO-5435	phase 3	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)	Diabetes

Therapeutic area mix

Oncology · 5
Cardiovascular · 3
Diabetes · 2
Bone metabolism / Osteoporosis · 1
Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Sanofi · 3 shared drug classes
Canadian Cancer Trials Group · 2 shared drug classes
Amgen · 2 shared drug classes
Bayer · 2 shared drug classes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
Addpharma Inc. · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Ono Pharmaceutical Co. Ltd:

Cite this brief

Drug Landscape (2026). Ono Pharmaceutical Co. Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ono-pharmaceutical-co-ltd. Accessed 2026-06-10.